In an experimental study of Crenolanib as a PDGFR restrainer, its margin of safety, stability, and pharmacokinetic properties have been briefly evaluated to facilitate moving forward toward clinical studies of Crenolanib as an FLT3 hampering agent in AML cases [108]. Here, PDGFRB is linked to acute myeloid leukemia.